Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
By Peter Yim
WHO updated “Therapeutics and COVID-19” on March 31, 2021 to include a recommendation on ivermectin. The recommendation was:
“We recommend not to use ivermectin in patients with COVID-19 except in the context of a clinical trial.”
The recommendation was made by the Guideline Development Group; 63 members consisting of “content experts, clinicians, patients, ethicists and methodologists”.
WHO explained that a vote on the recommendation was not necessary:
“While a priori voting rules informed procedures if the panel failed to reach consensus, these procedures proved unnecessary for this recommendation.”
Was there an “a priori” system in place for deciding when and how to abandon the “a priori” voting rules?How was consensus determined?Is it too late to take a vote?
WHO explained how they reached their “transparent and trustworthy recommendations”. They need to understand that bypassing a vote on the recommendation is the opposite of transparent and trustworthy.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).